Intas Pharmaceuticals Ltd - Company Profile
Powered by
All the data and insights you need on Intas Pharmaceuticals Ltd in one report.
- Save hours of research time and resources with
our up-to-date Intas Pharmaceuticals Ltd Strategy Report
- Understand Intas Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Intas Pharmaceuticals Catalyst Calendar
Proactively evaluate Intas Pharmaceuticals Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Intas Pharmaceuticals Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
07 Feb 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
12 Dec 2019 | Phase III Trial Completion | Intas Pharmaceuticals Ltd; Jaslok Hospital & Research Centre | - | gabapentin | Central Nervous System | Cerebral Palsy; Dystonia | Clinical Trial Registry |
02 Dec 2019 | Phase III Trial Initiation | Intas Pharmaceuticals Ltd; Lambda Therapeutic Research Ltd | - | bevacizumab biosimilar | Oncology | Lung Cancer; Malignant Neoplasms; Metastatic Lung Cancer; Non-Small Cell Lung Cancer | Clinical Trial Registry |
28 Nov 2019 | Phase III Trial Completion | Intas Pharmaceuticals Ltd; Jaslok Hospital & Research Centre | - | gabapentin | Central Nervous System | Cerebral Palsy | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer